This activity was originally presented at the 2024 HOPA Annual Conference in Tampa, Florida.
Program Description
With the emergence of Janus associated kinase (JAK) inhibitors as pivotal agents in managing myelofibrosis (MF), the role of oncology pharmacists has become increasingly vital in ensuring optimal patient outcomes. The selection and sequencing of JAK inhibitor therapies in MF are influenced by disease characteristics, patient comorbidities, and treatment response. Oncology pharmacists must stay abreast of emerging data for the JAK inhibitors, updates to treatment guidelines, and ongoing clinical trials to facilitate informed treatment decisions, especially in patients who are intolerant to or refractory to first-line JAK inhibitor therapy or who present with MF-associated anemia. This activity will examine strategies for evidence-based treatment sequencing in MF and equip pharmacists to optimize therapy while minimizing treatment-related adverse effects. Additionally, oncology pharmacists will develop strategies for proactive monitoring and management of common and rare adverse effects associated with JAK inhibitors.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: April 12, 2024
Expiration date: April 12, 2025
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Ensure appropriate treatment selection for individual patients with myelofibrosis (MF) considering patient- and disease-specific factors
- Identify signs and symptoms of disease progression in patients with MF and strategies for safe transition to subsequent treatment
- Implement evidence-based interventions to address symptoms of MF and associated treatments such as anemia and infection risk
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
